On September 1st, company co-founder Toni Speidel assumed the role of CEO. Simultaneously, the marketing and sales team was strengthened with the addition of two new Marketing & Sales Specialists. To further support the company’s expansion in China, a local Key Account Manager has also been appointed for the Chinese market.

In May, the VibroSense Meter® II received approval from China's National Medical Products Administration (NMPA), marking a significant milestone that paves the way for entry into the large Chinese market. Further updates on the delivery status will be communicated at a later date.

Meanwhile, China has recently introduced new restrictions on public procurement of medical devices from the EU. Our agreement with UMCare is not expected to be affected, as the contract value falls below the threshold of approximately EUR 5.3 million. However, the situation is being closely monitored.

In parallel with the China expansion, VibroSense Dynamics continues to strengthen its market presence in Europe, including forming partnerships with clinics to conduct research on the VibroSense Meter® II. Just before summer, a collaboration was initiated with the diabetic foot ulcer unit at the Complutense University of Madrid. The aim is to validate the VibroSense Meter® II in clinical practice and compare the technology with current methods for diagnosing diabetic neuropathy.

Another key milestone was receiving an Intention to Grant from the European Patent Office for a patent on a biomarker that can predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy. The patent will be valid for 20 years within the EU, and equivalent applications have been filed in the US, Japan, and China.

With a strengthened organisation and ongoing market initiatives, VibroSense Dynamics is well-positioned to take the next step in its growth journey.

For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com

“The new Gold Standard for reliable 
detection of nerve damage”

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers. 

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.